E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mental and behavioral disorders (F00-F99)
|
|
E.1.1.1 | Medical condition in easily understood language |
Mental disorders (F00-F99) |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective: To evaluate the efficacy at 3 months of immunotherapy for patients with psychiatric symptoms and proven auto-immunity (added to ongoing psychotropic treatment).
|
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives: - To assess the efficacy at 1, 6 and 12 months of immunotherapy added to ongoing psychotropic treatment, - To evaluate the prevalence of auto-immune psychosis in France, - To assess the safety of immunotherapy in case of psychiatric symptoms, - To evaluate the kinetic of auto-Ab at 3 months.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The inclusion criteria are common for the two steps - For Adult patient: • First acute or relapse of psychiatric disorder (most often psychotic diseases or bipolar disorders) defined by the BPRS-E scale. - For Children patient: • Child over 6 years old with a first acute or relapse of psychiatric disorder defined by the Kiddie sads-PL scale. - For all patients: • Informed consent of the patient or his legal representatives • Effective contraception for women of childbearing potential
|
|
E.4 | Principal exclusion criteria |
For the first step of the study (diagnostic) • Developmental disorder related to a genetic disease. • Co-existing disorder of severe neurological disease. • Chronic psychiatric disorders receiving ongoing neuroleptic treatment with efficacy. • Absence of consent from the patient or their legal representatives for the first step of the study • Pregnant or breastfeeding women.
For the second step of the study (Intervention): • Patient for whom a diagnosis of autoimmune disease would not be made or for whom participation in step 2 would not be validated by the multidisciplinary concertation (MDC) • Absence of consent from the patient or their legal representatives for the second step of the study • Hypersensitivity to the active substance (rituximab) or to murine proteins, or to any of the other excipients • Blood platelets < 75x109/L • Neutrophils < 1.5x109/L • Neoplastic pathology, • Hepatitis B or HIV infection, • Contraindication to immunosuppressant treatment (active severe infection, severely immunocompromised state). • Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease • Pregnancy at the randomization visit. • Concurrent enrolment in another pharmacological trial.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome is the remission of psychiatric symptoms at 3 months, defined as: - For adult patients: 20% decrease from baseline of BPRS-E scale - For patients <18years or adults patients included at adolescent age at 2nd step inclusion visit: clinically significant difference ≤3 from baseline of CBCL/6-18 (Child Behavior Checklist) scale.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
3 months after treatement initiation |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints linked with the secondary objectives are: - The remission of psychiatric symptoms in each group of participants to the Step 2 of the trial, at month 1, 6 and 12 - For adults patients: • Evaluation of severity CGI-S, CGI-I • Cognitive scales (GAF, MOCA) • Neurologic scales (KREBS, BUSH) • Psychiatric scales (BPRS-E, MINI) • Scale for psychosis evaluation PANSS • Scales for bipolar symptoms (MADRS, YMRS) • CBCL (only if they are included at adolescent age on step 2 inclusion visit and reach legal age during the step 2 of the study)
- For children patients: • Evaluation of severity CGI-S, CGI-I • CBCL
- Persistence rate of autoimmunity in psychiatric disorder at baseline for all participants to the Step 1 of the trial. - Level of NMDAr-Ab at 3 months in each group of participants to the Step 2 of the trial. - Frequency of serious and non-serious adverse events in each arm. - Frequency of infections in each arm.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
at month 1, 6 and 12 after treatment initiation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
ongoing psychotropic treatment |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 38 |
E.8.9.1 | In the Member State concerned days | |